A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs LEZ 763 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 09 Jun 2015 Results in 96 patients with type 2 diabetes mellitus presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 May 2013 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.